JP2023078173A5 - - Google Patents

Download PDF

Info

Publication number
JP2023078173A5
JP2023078173A5 JP2023029170A JP2023029170A JP2023078173A5 JP 2023078173 A5 JP2023078173 A5 JP 2023078173A5 JP 2023029170 A JP2023029170 A JP 2023029170A JP 2023029170 A JP2023029170 A JP 2023029170A JP 2023078173 A5 JP2023078173 A5 JP 2023078173A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023029170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023078173A (ja
Filing date
Publication date
Priority claimed from CN201810702492.7A external-priority patent/CN110656117A/zh
Priority claimed from CN201810703168.7A external-priority patent/CN110724695A/zh
Priority claimed from PCT/CN2018/095023 external-priority patent/WO2020010491A1/zh
Priority claimed from CN201810948193.1A external-priority patent/CN110846392A/zh
Priority claimed from PCT/CN2018/103937 external-priority patent/WO2020000641A1/zh
Priority claimed from CN201811221305.XA external-priority patent/CN111073899B/zh
Priority claimed from CN201811230856.2A external-priority patent/CN111068071A/zh
Priority claimed from JP2021521870A external-priority patent/JP2021529001A/ja
Priority claimed from PCT/CN2019/094136 external-priority patent/WO2020001657A1/en
Application filed filed Critical
Publication of JP2023078173A publication Critical patent/JP2023078173A/ja
Publication of JP2023078173A5 publication Critical patent/JP2023078173A5/ja
Pending legal-status Critical Current

Links

JP2023029170A 2018-06-29 2023-02-28 レーベル遺伝性視神経症を治療するための組成物及び方法 Pending JP2023078173A (ja)

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
CN201810702492.7A CN110656117A (zh) 2018-06-29 2018-06-29 一种编码人nadh脱氢酶亚单位6蛋白的核酸及其应用
CN201810703168.7 2018-06-29
CN201810703168.7A CN110724695A (zh) 2018-06-29 2018-06-29 一种编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CN201810702492.7 2018-06-29
PCT/CN2018/095023 WO2020010491A1 (zh) 2018-07-09 2018-07-09 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CNPCT/CN2018/095023 2018-07-09
CN201810948193.1 2018-08-20
CN201810948193.1A CN110846392A (zh) 2018-08-20 2018-08-20 一种重组腺相关病毒或含其的试剂盒及其应用
CNPCT/CN2018/103937 2018-09-04
PCT/CN2018/103937 WO2020000641A1 (zh) 2018-06-29 2018-09-04 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
CN201811221305.XA CN111073899B (zh) 2018-10-19 2018-10-19 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN201811221305.X 2018-10-19
CN201811230856.2A CN111068071A (zh) 2018-10-22 2018-10-22 基因治疗Leber遗传学视神经病变
CN201811230856.2 2018-10-22
PCT/CN2018/113799 WO2020082417A1 (zh) 2018-10-22 2018-11-02 基因治疗Leber遗传性视神经病变
CNPCT/CN2018/113799 2018-11-02
CNPCT/CN2018/118662 2018-11-30
PCT/CN2018/118662 WO2020077756A1 (zh) 2018-10-19 2018-11-30 Nd4蛋白的编码序列及其应用
CNPCT/CN2019/070461 2019-01-04
PCT/CN2019/070461 WO2020037938A1 (zh) 2018-08-20 2019-01-04 一种重组腺相关病毒或含其的试剂盒及其应用
JP2021521870A JP2021529001A (ja) 2018-06-29 2019-07-01 レーベル遺伝性視神経症を治療するための組成物及び方法
PCT/CN2019/094136 WO2020001657A1 (en) 2018-06-29 2019-07-01 Compositions and methods for treating leber's hereditary optic neuropathy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021521870A Division JP2021529001A (ja) 2018-06-29 2019-07-01 レーベル遺伝性視神経症を治療するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2023078173A JP2023078173A (ja) 2023-06-06
JP2023078173A5 true JP2023078173A5 (https=) 2024-02-06

Family

ID=72041345

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521870A Pending JP2021529001A (ja) 2018-06-29 2019-07-01 レーベル遺伝性視神経症を治療するための組成物及び方法
JP2023029170A Pending JP2023078173A (ja) 2018-06-29 2023-02-28 レーベル遺伝性視神経症を治療するための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021521870A Pending JP2021529001A (ja) 2018-06-29 2019-07-01 レーベル遺伝性視神経症を治療するための組成物及び方法

Country Status (9)

Country Link
US (3) US11034954B2 (https=)
EP (1) EP3814492A4 (https=)
JP (2) JP2021529001A (https=)
KR (2) KR20240014102A (https=)
AU (3) AU2019296451B2 (https=)
BR (1) BR112020026361A2 (https=)
CA (1) CA3103740A1 (https=)
MX (1) MX2020013772A (https=)
SG (1) SG11202012044QA (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
CA3109432A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CN112159841B (zh) * 2020-10-10 2022-03-01 苏州大学 基于cox10基因插入缺失多态性位点的心源性猝死易感性检测试剂盒

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
AU2668897A (en) 1996-04-19 1997-11-12 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US20010006948A1 (en) * 1998-11-25 2001-07-05 James D. Kang Gene transfer to intervertebral disc cells
US20020132978A1 (en) 2000-03-21 2002-09-19 Hans-Peter Gerber VEGF-modulated genes and methods employing them
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
US20040072774A1 (en) * 2002-02-23 2004-04-15 Giovanni Manfredi Methods for expressing and targeting mitochondrial-DNA-encoded peptides and uses thereof
US7405284B2 (en) * 2002-10-18 2008-07-29 University Of Florida Research Foundation, Inc. Reducing cellular dysfunction caused by mitochondrial gene mutations
EP1751275B1 (en) * 2004-06-01 2017-08-16 Avigen, Inc. Compositions and methods to prevent aav vector aggregation
US20130022979A1 (en) 2005-04-18 2013-01-24 Genesis Genomics Inc. 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER
ES2541771T3 (es) 2005-05-03 2015-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expresión de una proteína mitocondrial mediante un enfoque alotópico mejorado
CA2667705A1 (en) 2006-10-23 2008-05-29 University Of Florida Research Foundation, Inc. Suppression of mitochondrial oxidative stress
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
EP2565649B1 (en) 2007-06-20 2015-04-15 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
ES2563984T3 (es) 2008-10-22 2016-03-17 Quark Pharmaceuticals, Inc. Métodos para el tratamiento de trastornos oculares
DK2529020T3 (en) 2010-01-28 2018-08-06 Childrens Hospital Philadelphia SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
CN102517304B (zh) 2011-12-16 2013-08-28 中国农业科学院生物技术研究所 重组葡萄糖氧化酶的优化基因及其表达载体和应用
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US20160289674A1 (en) 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
CN102634527B (zh) 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US9066966B2 (en) * 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
US9567376B2 (en) * 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
EP2992892A1 (en) * 2014-09-05 2016-03-09 Universität zu Köln Fusion protein for use in the treatment of mitochondrial diseases
US10493141B2 (en) 2014-09-17 2019-12-03 The University Of Iowa Research Foundation Viral RNA segments as immunomodulatory agents and vaccine components
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂
HK1248570A1 (zh) * 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
EP3322297B1 (en) 2015-07-13 2024-12-04 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2018102672A1 (en) 2016-12-04 2018-06-07 Alavi Khorassani Moghadam Marcel Victor Methods for treating diseases related to mitochondrial stress
US20180207293A1 (en) 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
BR112019017327A2 (pt) * 2017-03-01 2020-04-14 Univ Pennsylvania terapia gênica para distúrbios oculares
EP3441069B1 (en) 2017-08-11 2023-04-05 Unity Biotechnology, Inc. Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
US20210163898A1 (en) 2018-04-16 2021-06-03 The Children's Hospital Of Philadelphia Mitochondrial rna import for treating mitochondrial disease
CN112384625A (zh) 2018-06-11 2021-02-19 珍视生物股份公司 重组aav载体及其使用方法
CN110846392A (zh) 2018-08-20 2020-02-28 武汉纽福斯生物科技有限公司 一种重组腺相关病毒或含其的试剂盒及其应用
CN111068071A (zh) 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
WO2020010491A1 (zh) 2018-07-09 2020-01-16 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN111073899B (zh) 2018-10-19 2021-01-01 武汉纽福斯生物科技有限公司 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CA3109432A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
WO2020038352A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用

Similar Documents

Publication Publication Date Title
JP2023171775A5 (https=)
JP2022184985A5 (https=)
JP2023103258A5 (https=)
JP2021184963A5 (https=)
JP2024116190A5 (https=)
JP2023145572A5 (https=)
JP2022068302A5 (https=)
JP2025176106A5 (https=)
JP2023181322A5 (https=)
JP2023022224A5 (https=)
JP2024045126A5 (https=)
JPWO2020148954A5 (https=)
JP2025098156A5 (https=)
JP2023093656A5 (https=)
JP2025090801A5 (https=)
JP2025094038A5 (https=)
JP2024149687A5 (https=)
JP2023085264A5 (https=)
JP2023156274A5 (https=)
JP2024099585A5 (https=)
JP2023100857A5 (https=)
JP2023078173A5 (https=)
JP2021529721A5 (https=)
JP2024059782A5 (https=)
JPWO2020252375A5 (https=)